nitazoxanide, two marketed first-line drugs against giardiasis. In particular, compound 4 (an indomethacin hybrid) was one of the most potent of the series, inhibiting G. intestinalis growth in vitro with an IC50 of 0.145 μM. Compound 4 was 38-times more potent than metronidazole and 8-times more active than nitazoxanide. The in vivo giardicidal effect of 4 was evaluated in a CD-1 mouse model obtaining
我们使用DCC活化的酰胺化反应设计并合成了5种新的5-硝基噻唑-NSAID嵌合体,作为硝唑尼特的类似物。化合物1 - 5进行了测试体外抗原生动物5的面板:2个amitochondriates(贾第虫肠,阴道毛滴虫)和3-动质体(墨西哥利什曼原虫,利什曼原虫亚马孙和克氏锥虫)。所有嵌合体均显示出广谱和有效的抗原生动物活性,IC 50值范围从低微摩尔到纳摩尔。化合物1 - 5甲硝唑和硝唑尼特(两种市售的抗贾第鞭毛虫病一线药物)的活性甚至更高。尤其是,化合物4(吲哚美辛杂化物)是该系列中最有效的化合物之一,在体外抑制小肠肠杆菌的生长, IC 50为0.145μM。化合物4的效力是甲硝唑的38倍,活性是硝唑烷的8倍。在体内的giardicidal效果4在CD-1小鼠模型中评价获得的1.709微克/ kg的半数有效剂量(3.53纳摩尔/千克),一个321倍并用甲硝唑1015倍的增加在有效性灌胃后和硝